Immunoglobulin A IgA Vasculitis Market Report 2026

Immunoglobulin A IgA Vasculitis Market Overview

• Immunoglobulin A IgA Vasculitis market size has reached to $1.63 billion in 2025 • Expected to grow to $2.21 billion in 2030 at a compound annual growth rate (CAGR) of 6.2% • Growth Driver: Rising Incidence Of Autoimmune Diseases Driving The Growth Of The Market Due To Increasing Prevalence And Environmental Triggers • Market Trend: Innovative Biologic Therapy Gains FDA Nod For Inflammation Control • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Immunoglobulin A IgA Vasculitis Market?

Immunoglobulin A (IgA) vasculitis is an autoimmune disease characterized by inflammation of small blood vessels, primarily due to IgA antibody deposits. It commonly affects the skin, joints, kidneys, and gastrointestinal tract and is characterized by a purplish rash, abdominal pain, and joint inflammation. The main treatment types of immunoglobulin A (IgA) vasculitis are medications, plasma exchange, supportive care, and immunosuppressive therapy. Medications are primarily used to reduce inflammation and alleviate symptoms such as joint pain, skin rashes, and kidney complications resulting from IgA deposits in small blood vessels that trigger immune responses. Diagnostic methods for IgA vasculitis typically involve blood tests, urinalysis, imaging studies, and tissue biopsy. Routes of administration for treatment include oral, injectable, and intravenous options and are delivered across various healthcare settings, including hospitals, specialty clinics, and homecare environments.

What Is The Immunoglobulin A IgA Vasculitis Market Growth Forecast?

The immunoglobulin a iga vasculitis market size is expected to see strong growth in the next few years. It will grow to $2.21 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising research on novel immunomodulatory drugs, increasing adoption of personalized autoimmune therapies, growing focus on long-term renal protection, expansion of biologic treatment pipelines, improved diagnostic imaging and biopsy techniques. Major trends in the forecast period include increasing focus on early and accurate disease diagnosis, rising adoption of targeted immunosuppressive therapies, growing use of biomarker-based disease monitoring, expansion of personalized treatment approaches, enhanced emphasis on renal outcome management.

Global Immunoglobulin A IgA Vasculitis Market Segmentation

1) By Treatment Type: Medications, Plasma Exchange, Supportive Care, Immunosuppressive Therapy 2) By Diagnosis Method: Blood Tests, Urinalysis, Imaging Studies, Biopsy 3) By Route Of Administration: Oral, Injectables 4) By End User: Hospitals, Specialty Clinics, Homecare Settings Subsegments: 1) By Medications: Corticosteroids, Immunosuppressants, Cyclophosphamide, Azathioprine, Mycophenolate Mofetil 2) By Plasma Exchange: Therapeutic Plasma Exchange, Plasma Filtration 3) By Supportive Care: Pain Management, Kidney Function Support, Blood Pressure Management 4) By Immunosuppressive Therapy: Methotrexate, Rituximab

What Are The Drivers Of The Immunoglobulin A IgA Vasculitis Market?

The rising incidence of autoimmune diseases is expected to propel the growth of the immunoglobulin A (IgA) vasculitis market going forward. Autoimmune diseases are conditions in which the body’s immune system mistakenly attacks its own healthy cells, tissues, or organs instead of protecting the body from infections and foreign substances. The rising prevalence of autoimmune disorders is primarily due to growing exposure to pollutants, which can disrupt immune regulation and trigger abnormal responses. Immunoglobulin A (IgA) vasculitis helps autoimmune diseases by triggering an immune response that leads to inflammation in small blood vessels, aiding in the understanding and potential treatment of various autoimmune conditions. For instance, in February 2024, according to the Vasculitis Foundation, a US-based non-profit organization, the annual incidence of IgA vasculitis in U.S. adults is about 2 cases per 100,000, though rates vary widely worldwide, ranging from roughly 60 to 550 cases per million. Therefore, the rising incidence of autoimmune diseases is driving the growth of the immunoglobulin A (IgA) vasculitis market. The rising focus on targeted therapies is expected to propel the growth of immunoglobulin A (IgA) vasculitis. Targeted therapies are treatments that specifically target and inhibit molecular abnormalities in cancer or other diseases to improve treatment precision and minimize harm to healthy cells. The rising focus on targeted therapies is primarily driven by the advancements in precision medicine, which enables personalized, more effective treatments based on individual genetic profiles. Targeted therapies aid immunoglobulin A (IgA) vasculitis treatment by focusing on specific immune pathways, minimizing systemic side effects. They improve disease management by reducing inflammation and preventing organ damage, enhancing patient outcomes and quality of life. For instance, in December 2024, according to the American Society of Gene and Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved six gene therapy products in 2023, up from five approvals in 2022. Therefore, the rising focus on targeted therapies is driving the growth of the immunoglobulin A (IgA) vasculitis market.

Key Players In The Global Immunoglobulin A IgA Vasculitis Market

Major companies operating in the immunoglobulin a iga vasculitis market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc, Intas Pharmaceuticals Ltd, Zydus Lifesciences Limited, Biogen Inc, Chugai Pharmaceutical Co Ltd, CSL Behring, AbbVie Inc, Johnson & Johnson, Bristol-Myers Squibb Company, UCB SA, Sanofi, GSK plc, Astellas Pharma Inc, Teva Pharmaceuticals USA Inc, Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co Ltd, Visterra Inc, Selecta Biosciences, Jiangsu HengRui Medicine Co Ltd, Travere Therapeutics Inc, Everest Medicines Ltd

Global Immunoglobulin A IgA Vasculitis Market Trends and Insights

Major companies operating in the immunoglobulin A (IgA) vasculitis market are focusing on developing innovative therapies, such as targeted biologics and immunomodulators, to reduce inflammation and prevent renal complications. Targeted biologics and immunomodulators are advanced therapies that modulate specific immune pathways to reduce inflammation and prevent immune-mediated damage in IgA vasculitis. For instance, in April 2025, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Vanrafia (atrasentan) for the treatment of primary immunoglobulin A nephropathy (IgAN). Vanrafia is a once-daily, oral, selective endothelin A receptor antagonist designed to reduce proteinuria in adults with primary IgAN who are at risk of rapid disease progression. It can be integrated into existing supportive care regimens without the need for a risk evaluation and mitigation strategy (REMS).

Regional Outlook

North America was the largest region in the immunoglobulin A (IgA) vasculitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Immunoglobulin A IgA Vasculitis Market?

The immunoglobulin A (IgA) vasculitis market consists of revenues earned by entities by providing services such as diagnostic testing, renal function monitoring, patient management programs, and clinical research and trials for novel therapeutics. The market value includes the value of related goods sold by the service provider or included within the service offering. The immunoglobulin A (IgA) vasculitis market also includes sales of corticosteroids, pain relievers, diagnostic kits, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Immunoglobulin A IgA Vasculitis Market Report 2026?

The immunoglobulin a iga vasculitis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulin a iga vasculitis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.